GLP Watchdog

Best Fitness Apps for Weight Loss in 2026 — Ranked & Reviewed

Our own evaluation and scoring of the leading weight-loss fitness apps for 2026.

Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more

By Ruth Calder · Enforcement Editor
Editorially reviewed (not clinically reviewed). Not medical advice · How we verify contentLast reviewed
Providers in this category are still being evaluated. Rankings will follow.
How we rank, and what counts as “legit”

Scoring for every provider on this page runs against our published six-factor rubric[1]: value, effectiveness, user experience, trust & safety, accessibility and support.

Each of Wegovy, Zepbound, Ozempic and Mounjaro holds its own separate FDA approval under its own NDA number[4][5]. Published Phase 3 efficacy for semaglutide at 2.4 mg (~14.9% mean weight loss across 68 weeks) comes from STEP 1[6]; those for tirzepatide (~20.9% at the 15 mg dose over 72 weeks) come from SURMOUNT-1[7]. In 2025 the SURMOUNT-5 head-to-head set the two against each other[8].

How much of an anti-obesity medication is covered varies widely between state Medicaid programs and between commercial plans[9][10]. Under IRS Publication 502, compounded GLP-1s and brand-name ones alike are generally FSA/HSA eligible where a prescription exists[11].

Price and states served both move. Read them off the seller's own site before you enroll.How our reviews work →

Frequently Asked Questions

Yes. The apps that work push the two behaviors most closely linked to weight loss: consistent activity, and tracking calories or food. No app out-trains a poor diet by itself. What it adds is accountability, habit tracking and structure, and those improve adherence meaningfully, which is where results actually come from.
Whichever one matches your goal and gets opened every day. Calorie and macro tracking suits diet-focused users, guided workouts suit activity, and hybrids cover both. Look for an accurate food database, progress tracking, and a plan you can keep up. The options are compared in the list above.
They complement it well. Appetite falls on a GLP-1, and an app helps hold muscle through resistance training while keeping activity and protein on track through rapid weight loss. Together they protect lean mass and support maintenance once the goal is reached.
Six weighted dimensions produce the score. Value (25%) and Effectiveness (25%) carry the most, then User Experience (15%) and Trust & Safety (15%), then Accessibility (10%) and Support (10%). Behind them sits our research into pricing data, clinical evidence, user reviews and publicly available information. Those weights then combine into one overall score out of 10.
The six-dimension methodology computes each score on its own, and no commercial relationship ever moves a provider's underlying number. Every provider's full score sits on its card for you to check. Some providers do hold affiliate agreements with us, which means a commission reaches us if you click through and buy. On the lists carrying the highest commercial intent — the weight-loss injection and shot lists, the semaglutide and tirzepatide lists, the compounded and cheapest molecule lists, and the fitness-app list — affiliate partners take the top positions. Every other list runs in score order, or in price order on the cheapest lists. That placement is disclosed here, on our methodology page, and on our affiliate-disclosure page.
Sources & methodology — as of September 2026
  1. 1.GLP Watchdog — GLP-1 Pricing Index 2026 (our independent dataset)— GLP Watchdog.
  2. 2.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
  3. 3.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
  4. 4.FDA — Wegovy (semaglutide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
  5. 5.FDA — Zepbound (tirzepatide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
  6. 6.STEP 1 Trial — Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding JPH et al.)— New England Journal of Medicine.PMID: 33567185.
  7. 7.SURMOUNT-1 Trial — Tirzepatide Once Weekly for the Treatment of Obesity (Jastreboff AM et al.)— New England Journal of Medicine.PMID: 35658024.
  8. 8.SURMOUNT-5 Trial — Tirzepatide vs. Semaglutide Head-to-Head in Obesity (Garvey WT et al.)— New England Journal of Medicine.PMID: 40334173.
  9. 9.KFF — Medicaid coverage research (anti-obesity & GLP-1 drug policy)— Kaiser Family Foundation.
  10. 10.CMS — Medicaid prescription drug coverage policy (state-by-state)— Centers for Medicare & Medicaid Services.
  11. 11.IRS Publication 502 — Medical and Dental Expenses (HSA/FSA eligibility)— Internal Revenue Service.

Related Rankings